CDC Website CDC Website

To Join the NPIN community or

You are here

National Institutes of Health

Addressing Health Disparities in NIDDK Diseases (R01)

This Funding Opportunity Announcement (FOA) invites research projects to improve understanding of the causes of high priority diseases in the United States and reducing/eliminating health disparities. Research is encouraged in the following high priority diseases within the scientific mission areas of the NIDDK: diabetes; obesity; nutrition-related disorders; hepatitis C; gallbladder disease; H.

HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3)

This FOA will support biphasic (i.e., two stage, multi-method) research projects that inform community response and promote comprehensive, integrated approaches to prevent HIV and hepatitis C virus (HCV) infection, along with associated comorbidities such as hepatitis B virus (HBV) infection and sexually transmitted diseases (STDs), among people who inject drugs (PWID) in rural US communities. Opioid injection and its consequences (e.g., HIV, HCV, HBV, STDs and overdose) are the primary foci here.

Collaborative Consortia for the Study of HIV-Associated Cancers: U.S. and Low-and Middle-Income Country Partnerships (U54)

The purpose of this Funding Opportunity Announcement (FOA) is to fund research on HIV-associated cancers in low- and middle-income countries (LMICs) through collaborative efforts between investigators in United States (U.S.) and investigators in LMICs. The FOA will also support the enhancement of research capacity of LMIC institutions for research in this area. The FOA solicits applications for Specialized Center Cooperative Agreements (U54) for research on HIV-associated cancers from research institutions in the U.S. and LMICs.

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24)

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse. These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigator–initiated research projects.

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21)

The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.

Understanding and Addressing the Multi-level Influences on Uptake and Adherence to HIV Prevention Strategies Among Adolescent Girls and Young Women in Sub-Saharan Africa (R21)

This initiative aims to: (1) enhance our understanding of the multi-level factors that influence HIV prevention strategy use among adolescent girls and young women (AGYW) in sub-Saharan Africa and (2) develop and test novel interventions to address these factors and enhance the uptake and adherence to HIV prevention strategies among AGYW in sub-Saharan Africa.

Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01)

The purpose of this FOA is to promote research to investigate the underlying molecular mechanisms of HIV infection-induced immune activation and inflammation in the presence of antiretroviral therapy (ART) agents and drugs of abuse. The ultimate goal is to obtain information for developing therapeutic interventions for attenuating chronic inflammation-associated comorbidities as well as for restoring or improving ART efficacy in HIV-infected drug-abusing populations.

Pages

Subscribe to RSS - National Institutes of Health